Clarity Pharmaceuticals Ltd

ASX:CU6 Stock Report

Market Cap: AU$1.8b

Clarity Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Clarity Pharmaceuticals's earnings have been declining at an average annual rate of -36.9%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 33.8% per year.

Key information

-36.9%

Earnings growth rate

-26.9%

EPS growth rate

Pharmaceuticals Industry Growth31.2%
Revenue growth rate33.8%
Return on equity-28.9%
Net Margin-367.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

Sep 23
We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Jan 03
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

May 29
We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Aug 24
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Jan 13
Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Revenue & Expenses Breakdown

How Clarity Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:CU6 Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2412-421146
31 Mar 2410-36841
31 Dec 239-31636
30 Sep 2310-28534
30 Jun 2310-25531
31 Mar 2310-23529
31 Dec 229-21526
30 Sep 228-23523
30 Jun 226-24519
31 Mar 226-21516
31 Dec 215-19512
30 Sep 214-15411
30 Jun 213-10410
31 Mar 213-9310
31 Dec 203-9210
30 Sep 203-828
30 Jun 203-737
30 Jun 193-432
30 Jun 182-221

Quality Earnings: CU6 is currently unprofitable.

Growing Profit Margin: CU6 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CU6 is unprofitable, and losses have increased over the past 5 years at a rate of 36.9% per year.

Accelerating Growth: Unable to compare CU6's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CU6 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).


Return on Equity

High ROE: CU6 has a negative Return on Equity (-28.93%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies